Login to Your Account



Mustang Bio saddles up with $94.5M private placement

By Michael Fitzhugh
Staff Writer

Thursday, February 2, 2017

Fortress Biotech Inc. subsidiary Mustang Bio Inc. closed on a $94.5 million private placement financing. It plans to use the funds to advance its two lead chimeric antigen receptor T-cell (CAR T) immunotherapies, MB-101 and MB-102.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription